Seattle-based M3 Biotechnology announced it has received a $1.4 million investment from the Alzheimer’s Drug Discovery Foundation, allowing it to begin preparing for clinical trials of its leading drug candidate. The drug is a novel therapy for Alzheimer’s that actually stops the deterioration of neurons, possibly halting the disease in its tracks. If successful, it would be a huge step forward in Alzheimer’s treatment as most therapies for the disease treat symptoms rather than the root cause. The ADDF was the company’s first investor, and its contribution spurred the startup past the valley of death, M3 Biotechnology founder and CEO Leen Kawas said in a press release. The company later raised $14 million from various other investors.